TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03273361

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compact Cycling Device
Description: Participants pedaled a compact cycling device while simultaneously working at a desk.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compact Cycling Device
Description: Participants pedaled a compact cycling device while simultaneously working at a desk.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compact Cycling Device
Description: Participants pedaled a compact cycling device while simultaneously working at a desk.
Study: NCT02698085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actual Diacutaneous Fibrolysis
Description: Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means of a set of metallic hooks ending a spatula with bevelled edges that help to treat the muscles and conjunctive tissues and trying to improve mobility between mobility between muscle planes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Diacutaneous Fibrolysis
Description: Sham Diacutaneous Fibrolysis is applied at a superficial level. A pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula but without effect in the muscle because no penetrate in deep tissue
Study: NCT02867579

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: evaluation of the child quality attachment (Strange situation)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: evaluation of the child quality attachment (Strange situation)
Study: NCT00993668

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - Two 0.9% saline subcutaneous (sc) injections at Week 0, Week 2, and Week 4 followed by two sc injections of Open-Label (OL) CZP 200 mg at Weeks 6, 8 and 10, then one sc injection of OL CZP 200 mg every two weeks from Week 12 until last drug administration (up to Week 32).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: Certolizumab pegol - Two 200 mg subcutaneous (sc) injections at Week 0, Week 2, and Week 4 followed by one sc injection of Open-Label (OL) CZP 200 mg from Week 6 until last drug administration (up to Week 32).
Study: NCT04470232

Intervention type: OTHER
Intervention: Self-assessment questionnaires
Description: 120 patients with coxofemoral pathologies will pass the SUSHI-score and the HOOS-12 score questionnaires.~The HAGOS (Hip and Groin Score) questionnaire will be also passed by the subject, for the convergent validity.
Study: NCT03138772

Intervention type: OTHER
Intervention: This is an observational study, no intervention used.
Description: No intervention is being used in this study.

Intervention type: OTHER
Intervention: This is an observational study, no intervention used.
Description: No intervention is being used in this study.
Study: NCT01236534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lubiprostone
Description: 24 mcg twice daily for 21 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo twice daily for 21 days.
Study: NCT01079663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 2.5 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo chip
Study: NCT04658238

Intervention type: OTHER
Intervention: Ocular microbiome
Description: Taxonomical and functional characterization of the ocular microbiome

Intervention type: OTHER
Intervention: Ocular microbiome
Description: Taxonomical and functional characterization of the ocular microbiome

Intervention type: OTHER
Intervention: Ocular immune system
Description: Functional characterization of the tear fluid proteome, histology of conjunctival tissue and molecular assays

Intervention type: OTHER
Intervention: Ocular immune system
Description: Functional characterization of the tear fluid proteome, histology of conjunctival tissue and molecular assays
Study: NCT00461032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast
Description: montelukast 5 mg tablet Once a day (QD) for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo to montelukast QD for 8 weeks
Study: NCT03212300

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise Training (AET)
Description: 20 sessions of AET over a 4 week period just prior to surgery
Study: NCT03619070

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training, LL
Description: In LL, the postmenopausal women will be submitted to 12 weeks of Resistance training with moderate volume (i.e. three sets per exercise) and low load (i.e. 30% of one repetition maximum)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training, HL
Description: In HL, the postmenopausal women will be submitted to 12 weeks of Resistance training with moderate volume (i.e. three sets per exercise) and high load (i.e. 80% of one repetition maximum)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training, HVHL
Description: In HVHL, the postmenopausal women will be submitted to 12 weeks of Resistance training with high volume (i.e. six sets per exercise) and hig load (i.e. 80% of one maximum repetition)

Intervention type: OTHER
Group type: OTHER
Intervention: Control group, CG
Description: The CG groups do not will performed the exercise.
Study: NCT00778960

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Slow Breathing
Description: The slowed breathing group will be trained on a breathing device, RESPeRATE, designed to reduce respiratory rate.They will practice with RESPeRATE once a week (for 6 weeks) in the laboratory with the research staff.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: The Mindfulness Body Scan meditation will be used for the mindfulness meditation group.Participants will be trained once a week (for six weeks) in the laboratory by the research staff.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation and slow breathing
Description: A structured Mindfulness breathing will be guided by the research staff during the lab trainings. The participant will sit upright and attempt to focus attention on his or her own breath as it passes the opening of the nostrils or on the rising and falling of the abdomen or chest. Whenever attention wanders from the breath, the participant will simply notice the distracting thought and then let it go as attention is returned to the breath. Training will be given once every week for 6 weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sitting Quietly
Description: The SQ control group's intervention will include sitting quietly and listening to a neutral-content book on tape to serve as a time and attention control at each laboratory session. They will also be asked to sit quietly at home daily.
Study: NCT04090255

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal puncture
Description: The use of a needle for entering pelvicalyceal system of the kidney and put a guide wire for further pcn

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal puncture
Description: The use of a needle for entering pelvicalyceal system of the kidney and put a guide wire for further pcn
Study: NCT00848731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nitric oxide
Description: nitric oxide gas is delivered by facemask
Study: NCT02765802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Lambda-1A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Lambda-1A
Study: NCT04373824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin 200 to 400 mcg per kg body weight
Study: NCT01290653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Deep dry needling until achieving twitch response of the muscle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strain-counterstrain technique
Description: A manual technique to release tension of painful muscles.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo manual technique
Description: A placebo technique, consisting of manual contact of the therapist with the patient without any further therapeutic approach
Study: NCT04595318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard clinical care first, followed by standard clinical care and varenicline
Description: Standard clinical care includes substance use disorder treatment program-based individual behavioral counseling at least once a month using motivational and cognitive behavioral strategies. Varenicline therapy includes a one month's supply of the medication in standard doses: 0.5 mg for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard clinical care and varenicline first, followed by standard clinical care
Description: Standard clinical care includes substance use disorder treatment program-based individual behavioral counseling at least once a month using motivational and cognitive behavioral strategies. Varenicline therapy includes a one month's supply of the medication in standard doses: 0.5 mg for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 21 days.
Study: NCT04999124

Intervention type: OTHER
Group type: OTHER
Intervention: Screening and studying characteristics
Description: Type 2 diabetes patients have a high risk of developing NAFLD. This was confirmed during previous research, a high prevalence of NAFLD among type 2 diabetes mellitus patients was found. Now we want to determine the characteristics of this population.
Study: NCT01290523

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Selective internal radiation therapy of the liver with Yttrium-90 glass microspheres (TheraSphere)
Description: Administration of Yttrium-90 TheraSphere glass microspheres into the hepatic artery
Study: NCT03071263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patiromer
Description: 2 packets/day starting dose, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 packets/day starting dose, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: 25 mg tablet/day starting dose, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: 25 mg tablet/day starting dose, administered orally
Study: NCT01366001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 33-BUP
Description: Sublingual administration, ALKS 33 + buprenorphine, administered once daily for 10 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 33
Description: Sublingual administration, ALKS 33 administered once daily for 10 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sublingual administration, Placebo administered once daily for 10 consecutive days.
Study: NCT01665469

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tomato extracted lycopene

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01169025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Subjects receive 0.3 mg/kg IV ketamine over 5 minutes and are evaluated every 10 minutes. Residual or recurring pain will be treated as needed with adjunctive open-label bolus dosing of IV fentanyl (1 mcg/kg) followed by repeat boluses as needed every 10 minutes during the flight. For this open-label portion of the flight, subjects are asked if they need additional pain medication every 10 minutes, unless an earlier, spontaneous request is made by the subject or the provider determines that more is needed. For the potential of rare ketamine side effects (dysphoria, anxiety, or agitation), 2 mg IV midazolam is given every 5 minutes as needed for any of these symptoms. Vital signs are measured continuously throughout the protocol. Blood pressure is measured at 5 minute intervals.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Subjects receive 1 mcg/kg IV fentanyl over 5 minutes. After first dose administration, subjects are evaluated every 10 minutes. Residual or recurring pain is treated as needed with adjunctive open-label bolus dosing of IV fentanyl (1 mcg/kg) followed by repeat boluses as needed every 10 minutes during the flight. For this open-label portion of the flight, flight nurses will query participants regarding their desire for additional pain medication every 10 minutes unless an earlier, spontaneous request is made by the participant or the provider determines that more is needed. Vital signs are measured continuously throughout the protocol. Blood pressure is measured at 5 minute intervals.
Study: NCT04731285

Intervention type: DIAGNOSTIC_TEST
Intervention: Pressure wire fractional flow reserve
Description: Pressure wire is inserted into coronary arteries. The ratio of the average distal pressure and average aorta pressure is FFR.

Intervention type: DIAGNOSTIC_TEST
Intervention: CFD-based RuiXin-FFR
Description: CT-FFR was evaluated in a blinded fashion with a Coarse-to-Fine Subpixel algorithm for lumen contour
Study: NCT02640638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CenteringPregnancy
Description: 8-12 pregnant women whose due dates are in the same month will receive ten 2-hour group prenatal care sessions according to the standard curriculum provided by the Centering Healthcare Institute.
Study: NCT02994563

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thrombectomy Device
Description: The Amnis Thrombectomy Device is intended to restore blood flow by removing thrombus from intracranial vessels in patients experiencing ischemic stroke
Study: NCT02843906

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lombar Punction
Description: cerebrospinal fluid testing at screening and M36

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lombar Punction
Description: cerebrospinal fluid testing at screening and M36

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lombar Punction
Description: cerebrospinal fluid testing at screening and M36

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI done at screening and M36

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI done at screening and M36

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI done at screening and M36

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Positron-Emission Tomography (TEP) /(FDG)
Description: TEP/FDG done at screening and M36

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Positron-Emission Tomography (TEP) /(FDG)
Description: TEP/FDG done at screening and M36

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Positron-Emission Tomography (TEP) /(FDG)
Description: TEP/FDG done at screening and M36

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychiatric tests

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychiatric tests

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychiatric tests

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological Tests
Description: done at screening, M12, M24 and M36

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological Tests
Description: done at screening, M12, M24 and M36

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological Tests
Description: done at screening, M12, M24 and M36

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Apolipoprotein (ApoE) detection
Description: ApoE detection done at screening

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Apolipoprotein (ApoE) detection
Description: ApoE detection done at screening

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Apolipoprotein (ApoE) detection
Description: ApoE detection done at screening
Study: NCT03146611

Intervention type: DIAGNOSTIC_TEST
Intervention: nCD64
Description: neutrophil CD64

Intervention type: DIAGNOSTIC_TEST
Intervention: nCD64
Description: neutrophil CD64

Intervention type: DIAGNOSTIC_TEST
Intervention: Neutrophil/Lymphocyte Ratio
Description: Neutrophil/ lymphocyte ratio

Intervention type: DIAGNOSTIC_TEST
Intervention: Neutrophil/Lymphocyte Ratio
Description: Neutrophil/ lymphocyte ratio
Study: NCT04234620

Intervention type: DRUG
Intervention: Toripalimab injection
Description: 240 mg/6 mL/vial. The recommended dose of Toripalima is 3 mg/kg, intravenous infusion every 2 weeks until disease progression or intolerable toxicity.
Study: NCT03847844

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical cord derived mesenchymal stem cell
Description: Umbilical cord derived mesenchymal stem cell

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study: NCT04582786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Repeated bolus according to pain score

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine HCl
Description: Infusion of morphine HCl solution for intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine HCl
Description: Infusion of morphine HCl solution for intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STR-324
Description: Infusion of solution for intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STR-324
Description: Infusion of solution for intravenous administration
Study: NCT04070365

Intervention type: DEVICE
Intervention: FLEX Vessel Prep System followed by angioplasty
Description: Eligible Arteriovenous Fistula (AVF)/Arteriovenous Graft (AVG) will be treated with the FLEX Vessel Prep system followed by angioplasty.
Study: NCT04154046

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tenotomy(cutting) of flexor tendons is performed with needle
Description: Patient is placed in seated posture with feet elevated. The toe(s) with hammer, mallet or claw toe deformity is anesthetized by a digital toe block with 1-5 ml of 1% lidocaine administered for each toe. The toe digital block is administered through a plantar approach, at the web level of the deformed toe(s), with a 0,6 mm diameter and 30mm long needle.~After anesthetizing the toe(s) the plantar aspect of the toe at web level is disinfected with an alcohol based disinfectant twice.~Both the long and short flexors are then severed with a 1.2mm diameter and 40mm long needle through a plantar approach, immediately proximal to the web level of the toe.~After the procedure a dry gauze bandage is applied and the patients treated foot/feet is/are elevated for 20 minutes to achieve haemostasis, and the bandage is checked for bleeding before discharge.
Study: NCT02428777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Women will receive oral tramadol 100 mg 1 hour before the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Women will receive oral diclofenac 100 mg 1 hour before the procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Women will receive an oral placebo 1 hour before the procedure
Study: NCT03360123

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam Hydrochloride 2Mg/mL Syrup
Description: Midazolam HCl Syrup 0.5mg/kg (Max: 15mg) taken 10-15 minutes prior to dental treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triazolam 0.125 MG
Description: Triazolam: 0.125mg tablet taken 30 minutes prior to dental treatment.
Study: NCT01673828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopregnanolone injection
Description: Allopregnanolone intravenous solution in 0.9% sodium chloride injection with 6% sulfobutyl ether β-cyclodextrin sodium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Placebo intravenous solution, 0.9% sodium chloride injection with 6% sulfobutyl ether β-cyclodextrin sodium
Study: NCT04364828

Intervention type: GENETIC
Group type: OTHER
Intervention: Whole Genome Analysis
Description: Whole Genome Analysis with whole transcriptome analysis and deoxyribonucleic acid (DNA) methylation analysis using Methylation beadchip (EPIC) arrays

Intervention type: GENETIC
Group type: OTHER
Intervention: T-cell receptor (TCR) repertoire
Description: Longitudinal analysis of TCR repertoire of Cluster of Differentiation 4+ (CD4+) and CD8+ T cells from blood samples (Peripheral Blood Mononuclear Cells, PBMCs) from clinically characterized patients

Intervention type: GENETIC
Group type: OTHER
Intervention: SARS-CoV-2 viral composition
Description: Determined by Next Generation sequencing
Study: NCT02784795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3039478
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3039478
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3039478
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3039478
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3039478
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taladegib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023414
Description: Administered orally
Study: NCT03952013

Intervention type: OTHER
Intervention: To explore health literacy levels in patients hospitalized for acute neuro-cardiovascular diseases i.e. stroke, myocardial infarction, or heart failure
Description: All patients included and followed within one of the three cohorts studies: LOOP-HF, HIBISCUS-STEMI and HIBISCUS-STROKE who accepted to participate in the study, will be contacted by phone (attempted calls are set to 3 to reach the patient), mail or during a consultation, to answer to a health literacy questionnaire. The patient will participate in the study only once. The estimated duration is therefore estimated at 1 day for each patient and two month for the study. Thanks to the many following periods within the cohorts (6 months, 1 year and 18 month), we will measure health literacy at different times of the care.
Study: NCT02103309

Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A contact lenses